Retapamulin: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Topical/Cutaneous
Bacterial skin infections due to methicillin-susceptible Staphylococcus aureus, Bacterial skin infections due to Streptococcus pyogenes, Impetigo

Adult: As 1% ointment: Apply onto affected area bid for 5 days. Re-evaluate if there is no response after 3 days of treatment. Total treatment area: ≤100 cm² total body surface area.
Child: As 1% ointment: ≥9 mth: Apply onto affected area bid for 5 days. Total treatment area: ≤2% of total body surface area.

Contraindications

Hypersensitivity.

Special Precautions

Discontinue use if skin irritation occurs. Prolonged use may result in fungal or bacterial superinfection. Re-evaluate if there is no response within 3 days. Children <9 mth. Pregnancy, lactation.

Adverse Reactions

Headache, pyrexia, pruritus, eczema, diarrhoea. Application site irritation, pain, erythema, contact dermatitis.

Action

Description: Retapamulin is a pleuromutilin antibacterial isolated from the fungus Clitopilus passeckerianus. It is a bacteriostatic agent that works by inhibiting biosynthesis of bacterial protein by binding at protein L3 on the ribosomal 50S subunit. It also inhibits peptidyl transfer and blocks P-site interactions at this site, thus preventing the formation of active 50S ribosomal subunits.
Pharmacokinetics:
Absorption: Topical admin: Only very small amounts are absorbed into the systemic circulation.
Distribution: 94% bound to plasma proteins.
Metabolism: Extensively hepatically metabolised by mono-oxygenation and di-oxygenation to multiple metabolites.

Storage

Store between 15-30°C.

MIMS Class

Other Antibiotics

Disclaimer: This information is independently developed by MIMS based on Retapamulin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com